Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling

Journal of Virology

Volumn 86, Issue 16, 2012, Pages 8581-8591

  Kumthip, Kattareeya ^a,b   Chusri, Pattranuch ^a,b   Jilg, Nikolaus ^a   Zhao, Lei ^a   Fusco, Dahlene N ^a   Zhao, Hong ^a,c   Goto, Kaku ^a   Cheng, Du ^a   Schaefer, Esperance A ^a   Zhang, Leiliang ^a   Pantip, Chansom ^b   Thongsawat, Satawat ^b   O'Brien, Amornrat ^b   Peng, Lee F ^a   Maneekarn, Niwat ^b   Chung, Raymond T ^a   Lin, Wenyu ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Faculty of Medicine Chiang Mai University   (Thailand)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DACLATASVIR; INTERFERON; MESSENGER RNA; NONSTRUCTURAL PROTEIN 5A; STAT1 PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC VARIABILITY; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INTERFERON STIMULATED GENE; MOLECULAR DYNAMICS; NONHUMAN; NONSTRUCTURAL PROTEIN 5A GENE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VIRUS GENE; VIRUS RECOMBINANT; VIRUS REPLICATION;

HEPACIVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON TYPE I; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN INTERACTION MAPPING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84865086668     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00533-12     Document Type: Article

References (50)

1. Barth H, Liang TJ, Baumert TF. 2006. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology 44:527-535.
2. Cai Z, et al. 2005. Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J. Virol. 79:13963-13973.
3. Chen L, et al. 2005. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 128:1437-1444.
4. Darnell JE, Jr, Kerr IM, Stark GR. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415-1421.
5. Ferenci P, et al. 2005. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ ribavirin. J. Hepatol. 43:425-433.
6. Francois C, et al. 2000. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR-mediated control of protein synthesis. J. Virol. 74:5587-5596.
7. Fridell RA, et al. 2011. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J. Virol. 85:7312-7320.
8. Fridell RA, Qiu D, Wang C, Valera L, Gao M. 2010. Resistance analysis of the hepatitisCvirus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob. Agents Chemother. 54:3641-3650.
9. Fried MW, et al. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347:975-982.
10. Gale M, Jr, et al. 1998. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol. Cell. Biol. 18:5208-5218.
11. Gale MJ, Jr, et al. 1997. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 230:217-227.
12. Gao M, et al. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100.
13. Garcia-Sastre A, Biron CA. 2006. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 312:879-882.
14. Gong GZ, Cao J, Jiang YF, Zhou Y, Liu B. 2007. Hepatitis C virus non-structural 5A abrogates signal transducer and activator of transcription-1 nuclear translocation induced by IFN-alpha through dephosphorylation. World J. Gastroenterol. 13:4080-4084.
15. Hadziyannis SJ, et al. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140:346-355.
16. Hansurabhanon T, et al. 2002. Infection with hepatitis C virus among intravenous-drug users: prevalence, genotypes and risk-factor-associated behaviour patterns in Thailand. Ann. Trop. Med. Parasitol. 96:615-625.
17. He XS, et al. 2006. Global transcriptional response to interferon is a determinant of HCV treatment outcome and is modified by race. Hepatology 44:352-359.
18. He Y, et al. 2002. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J. Virol. 76:9207-9217.
19. Honda K, Yanai H, Takaoka A, Taniguchi T. 2005. Regulation of the type I IFN induction: a current view. Int. Immunol. 17:1367-1378.
20. Hoofnagle JH, et al. 2003. Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology 38:66-74.
21. Huang Y, Staschke K, De Francesco R, Tan SL. 2007. Phosphorylation of hepatitisCvirus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? Virology 364:1-9.
22. Hugle T, et al. 2001. The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 284:70-81.
23. Ide Y, Tanimoto A, Sasaguri Y, Padmanabhan R. 1997. Hepatitis C virus NS5A protein is phosphorylated in vitro by a stably bound protein kinase from HeLa cells and by cAMP-dependent protein kinase A-alpha catalytic subunit. Gene 201:151-158.
24. Kang SM, Won SJ, Lee GH, Lim YS, Hwang SB. 2010. Modulation of interferon signaling by hepatitis C virus non-structural 5A protein: implication of genotypic difference in interferon treatment. FEBS Lett. 584: 4069-4076.
25. Kohashi T, et al. 2006. Site-specific mutation of the interferon sensitivitydetermining region (ISDR) modulates hepatitis C virus replication. J. Viral Hepat. 13:582-590.
26. Kumthip K, et al. 2011. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy. J. Viral Hepat. 18:e117- e125. doi:10.1111/j.1365-2893.2010.01379.x.
27. Lan KH, et al. 2007. HCV NS5A inhibits interferon-alpha signaling through suppression of STAT1 phosphorylation in hepatocyte-derived cell lines. J. Hepatol. 46:759-767.
28. Lin W, et al. 2005. Hepatitis C virus expression suppresses interferon signaling by degrading STAT1. Gastroenterology 128:1034-1041.
29. Lin W, et al. 2006. Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain. J. Virol. 80:9226-9235.
30. Lin W, et al. 2010. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaB-dependent manner. Gastroenterology 138:2509-2518, 2518.e1. doi:10.1053/j.gastro.2010.03.008.
31. Lin W, et al. 2011. HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J. Biol. Chem. 286:2665-2674.
32. Lindenbach BD, et al. 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-626.
33. Machida K, et al. 2010. c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology 52:480-492.
34. Mangia A, et al. 2005. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N. Engl. J. Med. 352:2609-2617.
35. Mbow ML, Sarisky RT. 2004. What is disrupting IFN-alpha's antiviral activity? Trends Biotechnol. 22:395-399.
36. Neumann AU, et al. 2000. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J. Infect. Dis. 182:28-35.
37. Niwa H, Yamamura K, Miyazaki J. 1991. Efficient selection for highexpression transfectants with a novel eukaryotic vector. Gene 108:193-199.
38. Pawlotsky JM. 2003. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res. 59:1-11.
39. Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J. 2011. RecombinantHCVvariants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-alpha. Gastroenterology 140:1032-1042.
40. Taylor DR, Shi ST, Lai MM. 2000. Hepatitis C virus and interferon resistance. Microbes Infect. 2:1743-1756.
41. Tellinghuisen TL, Foss KL, Treadaway J. 2008. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog. 4:e1000032. doi:10.1371/journal.ppat.1000032.
42. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE, Rice CM. 2004. The NS5A protein of hepatitis C virus is a zinc metalloprotein. J. Biol. Chem. 279:48576-48587.
43. Tsai YH, et al. 2008. The non-structural 5A protein of hepatitis C virus exhibits genotypic differences in interferon antagonism. J. Hepatol. 49: 899-907.
44. Velazquez L, Fellous M, Stark GR, Pellegrini S. 1992. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell 70:313-322.
45. Wakita T, et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
46. Watanabe H, et al. 2001. Number and position of mutations in the interferon (IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. J. Infect. Dis. 183:1195-1203.
47. Wohnsland A, Hofmann WP, Sarrazin C. 2007. Viral determinants of resistance to treatment in patients with hepatitis C. Clin. Microbiol. Rev. 20:23-38.
48. Zeuzem S, et al. 2004. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 40:993-999.
49. Zhang L, et al. 2011. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J. Hepatol. 55:289-298.
50. Zhong J, et al. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U. S. A. 102:9294-9299.